Risk stratification on the basis of Deauville score on PET-CT and the presence of Epstein-Barr virus DNA after completion of primary treatment for extranodal natural killer/T-cell lymphoma, nasal type: A multicentre, retrospective analysis

The Lancet Haematology

Volumn 2, Issue 2, 2015, Pages e66-e74

  Kim, Seok Jin ^a   Choi, Joon Young ^a   Hyun, Seung Hyup ^a   Ki, Chang Seok ^a   Oh, Dongryul ^a   Ahn, Yong Chan ^a   Ko, Young Hyeh ^a   Choi, Sunkyu ^a   Jung, Sin Ho ^a   Khong, Pek Lan ^b   Tang, Tiffany ^c   Yan, Xuexian ^d   Lim, Soon Thye ^c   Kwong, Yok Lam ^b   Kim, Won Seog ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b QUEEN MARY HOSPITAL   (Hong Kong)

^c DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^d SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; CARBOPLATIN; CISPLATIN; DEXAMETHASONE; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; METHOTREXATE; OXALIPLATIN; VIRUS DNA;

ADOLESCENT; ADULT; AGED; ARTICLE; ASSESSMENT OF HUMANS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DEATH; DEAUVILLE SCORE; EPSTEIN BARR VIRUS; HUMAN; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; NK T CELL LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; TREATMENT FAILURE; TREATMENT OUTCOME; CHEMORADIOTHERAPY; CLINICAL TRIAL; DISEASE FREE SURVIVAL; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HONG KONG; ISOLATION AND PURIFICATION; LYMPHOMA, EXTRANODAL NK-T-CELL; MALE; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PROGNOSIS; RISK ASSESSMENT; SINGAPORE; SOUTH KOREA; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHEMORADIOTHERAPY; DISEASE-FREE SURVIVAL; DNA, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HERPESVIRUS 4, HUMAN; HONG KONG; HUMANS; LYMPHOMA, EXTRANODAL NK-T-CELL; MALE; MIDDLE AGED; POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEOUL; SINGAPORE; YOUNG ADULT;

EID: 84923762894     PISSN: None     EISSN: 23523026     Source Type: Journal    
DOI: 10.1016/S2352-3026(15)00002-2     Document Type: Article

References (23)

1. Yamaguchi M, Tobinai K, Oguchi M, et al. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. J Clin Oncol 2009, 27:5594-5600.
2. Kim SJ, Kim K, Kim BS, et al. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-cell lymphoma: Consortium for Improving Survival of Lymphoma study. J Clin Oncol 2009, 27:6027-6032.
3. Kim SJ, Yang DH, Kim JS, et al. Concurrent chemoradiotherapy followed by L-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL08-01 phase II study. Ann Hematol 2014, 93:1895-1901.
4. Yamaguchi M, Kwong YL, Kim WS, et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol 2011, 29:4410-4416.
5. Kwong YL, Kim WS, Lim ST, et al. SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. Blood 2012, 120:2973-2980.
6. 18F-FDG PET in oncology. J Nucl Med 2008, 49:480-508.
7. 18F-FDG PET in patients with diffuse large B-cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy. J Nucl Med 2009, 50:527-533.
8. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007, 25:579-586.
9. 18F-FDG PET/CT for initial staging of nasal type natural killer/T-cell lymphoma: a comparison with conventional staging methods. J Nucl Med 2013, 54:1039-1044.
10. Barrington SF, Qian W, Somer EJ, et al. Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 2010, 37:1824-1833.
11. 18F-FDG PET/CT scan for early response assessment of SMILE therapy in natural killer/T-cell lymphoma: a prospective study from a single center. J Nucl Med 2014, 55:911-916.
12. Ito Y, Kimura H, Maeda Y, et al. Pretreatment EBV-DNA copy number is predictive of response and toxicities to SMILE chemotherapy for extranodal NK/T-cell lymphoma, nasal type. Clin Cancer Res 2012, 18:4183-4190.
13. Suzuki R, Yamaguchi M, Izutsu K, et al. Prospective measurement of Epstein-Barr virus-DNA in plasma and peripheral blood mononuclear cells of extranodal NK/T-cell lymphoma, nasal type. Blood 2011, 118:6018-6022.
14. Kwong YL, Pang AW, Leung AY, Chim CS, Tse E Quantification of circulating Epstein-Barr virus DNA in NK/T-cell lymphoma treated with the SMILE protocol: diagnostic and prognostic significance. Leukemia 2014, 28:865-870.
15. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999, 17:1244.
16. Kim HS, Kim KH, Kim KH, et al. Whole blood Epstein-Barr virus DNA load as a diagnostic and prognostic surrogate: extranodal natural killer/T-cell lymphoma. Leuk Lymphoma 2009, 50:757-763.
17. Germi R, Lupo J, Semenova T, et al. Comparison of commercial extraction systems and PCR assays for quantification of Epstein-Barr virus DNA load in whole blood. J Clin Microbiol 2012, 50:1384-1389.
18. Lee J, Suh C, Park YH, et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol 2006, 24:612-618.
19. Kim SJ, Kim WS Treatment of localized extranodal NK/T cell lymphoma, nasal type. Int J Hematol 2010, 92:690-696.
20. Meignan M, Barrington S, Itti E, Gallamini A, Haioun C, Polliack A Report on the 4th International Workshop on Positron Emission Tomography in Lymphoma held in Menton, France, 3-5 October 2012. Leuk Lymphoma 2014, 55:31-37.
21. Biggi A, Gallamini A, Chauvie S, et al. International validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: interpretation criteria and concordance rate among reviewers. J Nucl Med 2013, 54:683-690.
22. Gallamini A, Barrington SF, Biggi A, et al. The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. Haematologica 2014, 99:1107-1113.
23. Tychyj-Pinel C, Ricard F, Fulham M, et al. PET/CT assessment in follicular lymphoma using standardized criteria: central review in the PRIMA study. Eur J Nucl Med Mol Imaging 2014, 41:408-415.